Mrs. Paula Abola| Toxicology | Best Researcher Award

Postdoctoral Fellowship at University of Jamestown, Germany.

Paula Abola is a highly qualified researcher with a strong academic background and significant contributions to Parkinson’s Disease research. Her expertise spans pharmaceutical management, clinical drug development, and medicinal chemistry, with extensive experience in clinical trials, regulatory affairs, and academia.

Publication Profile

Orcid

Education:

Paula Abola has a strong academic background in clinical research and pharmaceutical sciences. She is set to undertake a Postdoctoral Fellowship in Pharmaceutical Management at Sabi University, Canada, with a focus on Parkinson’s Disease (May 2027). She is currently pursuing a Doctor of Philosophy (PhD) in Clinical Research at the University of Jamestown, USA, emphasizing Parkinson’s Disease and shared decision-making in pharmacological management (May 2026). She completed her Master of Science in Clinical Drug Development at Queen Mary University of London, UK, in August 2023, with her dissertation exploring the efficacy of Monoamine Oxidase-B Inhibitor Rasagiline versus Liquid Levodopa-Carbidopa ND0612 Medication. She also holds a Bachelor of Science in Medicinal Chemistry & Chemical Biology from Jacobs University Bremen, Germany (June 2022).

Professional Experience:

Paula has held multiple academic and clinical roles. She currently serves as a Professor at Atlantic International University, USA (2025–Present), where she lectures in Chemical Biology. She also holds positions as an Adjunct Professor at Constructor University, Germany (2025–Present) and the University of Jamestown, USA (2024), mentoring students and lecturing on topics such as Causation and Correlation, Leadership, and Ethics.In the clinical sector, she worked as a Clinical Trial Regulatory Specialist at IQVIA, Germany (2024–2025), ensuring compliance in site activation and regulatory documentation. Previously, she served as a Remote Site Monitor and Clinical Trial Coordinator at Thermo Fisher Scientific, Germany (2022–2024), supporting regulatory submissions and monitoring clinical trials. Her early experience includes roles as an Analytical Chemist at Sirius Fine Chemicals SiChem GmbH, Germany (2019–2022) and Union Med PHOENIX Pharmacy Partnership, Latvia (2021–2022), specializing in high-performance liquid chromatography (HPLC) and mass spectrometry analyses.

Skills:

Paula has expertise in clinical research, pharmaceutical management, regulatory compliance, and trial coordination. She is skilled in data analysis, high-performance liquid chromatography (HPLC), gas chromatography (GC), nuclear magnetic resonance (NMR), and mass spectrometry. Additionally, she has strong mentoring, teaching, and academic research capabilities.

Awards & Recognitions:

Her academic excellence is reflected in her Summa Cum Laude distinction in her PhD program and Cum Laude in both her Master’s and Bachelor’s degrees. She has also been actively recognized in clinical research for her contributions to Parkinson’s Disease studies.

Research Focus:

Paula’s primary research interests center around Parkinson’s Disease, particularly in pharmacological management, shared decision-making, and movement disorders. Her recent work includes systematic reviews and meta-analyses on monoamine oxidase-B inhibitors, liquid subcutaneous Levodopa-Carbidopa, and adverse event incidences in Parkinson’s patients. She is also actively engaged in patient-practitioner knowledge studies and intra-individual voice variations in Parkinson’s Disease.

Top Noted Publication

Liquid Subcutaneous Levodopa-Carbidopa ND0612 Effects on Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Authors: Paula Abola, Mitchell Wolden, Kristin Lefebvre
Year: 2024
Journal: Advances in Parkinson’s Disease

Monoamine Oxidase-B Inhibitor Rasagiline Effects on Motor and Non-Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Authors: Paula Abola, Mitchell Wolden
Year: 2024
Journal: Advances in Parkinson’s Disease

Conclusion

Paula Abola is an outstanding candidate for the Best Researcher Award, particularly in the fields of neuropharmacology, clinical trials, and Parkinson’s Disease management.
Her strong academic record, extensive publications, and leadership in movement disorder societies make her a compelling nominee. While her research is highly specialized, expanding into interdisciplinary innovation, AI applications, and broader pharmaceutical collaborations could further solidify her position as a top researcher.

Dr. Amal Shouair | Toxicology | Best Researcher Award

Head of clinical research unit at deputy manger of kafer eldwar general hospital, Egypt

Dr. Amal Shouair is a clinical pharmacy expert, researcher, and healthcare educator. She is the Deputy Manager at Kafer Eldwar General Hospital and serves as Head of the Clinical Pharmacy Unit and Training Department. With a strong background in clinical research, antimicrobial resistance, and pharmacoeconomics, she has contributed significantly to hospital training programs, clinical protocols, and national health initiatives. An alumnus of Harvard Medical School and a recognized TOT trainer, she continues to advance healthcare practices through education, research, and policy development.

Publication Profile

Orcid

Educational Details

Dr. Amal Shouair earned her Bachelor of Pharmacy with an excellence degree with honors from Alexandria University in 2006. She later completed a Diploma in Clinical Pharmacy from the same institution. She is currently a Master’s researcher in Microbiology and Immunity and has pursued postgraduate studies in Clinical Research at Harvard Medical School, where she is an alumnus of the ECSRT scholarship program. Dr. Shouair has also undertaken specialized training in leadership in medicine at Harvard Medical School and completed a professional government official program at the National Training Academy. Additionally, she was recognized among the top 10 participants in Egypt’s TOT program at Princess Fatma Academy.

Professional Experience

Dr. Amal Shouair serves as the Deputy Manager at Kafer Eldwar General Hospital and holds multiple key positions, including Head of the Clinical Pharmacy Unit and Head of the Training Department since 2016. She is also a Clinical Research Department Coordinator and an official Clinical Pharmacy Trainer for the Egyptian Fellowship Program.

Her experience includes supervising and lecturing in summer training programs for third-year pharmacy students at Alexandria University, serving as a Clinical Pharmacy and Pharmaceutical Care Lecturer, and acting as a Medical Club Coordinator at her hospital. She has been actively involved in educational programs on COVID-19 protocols, training over 400 medical staff members.

Dr. Shouair has also contributed to nursing education, focusing on safe medication use in critical care departments, and has developed and implemented several antibiotic stewardship programs, particularly in neonatal intensive care units (NICU), improving patient care while optimizing antimicrobial use. She has played a significant role in the “Drug Misuse Crisis” awareness campaign under the Elbehira Health Directorate, delivering lectures on antibiotic misuse and resistance across healthcare institutions.

Additionally, she has taken part in hospital administration, infection control, and strategic planning initiatives, with training in Total Quality Management (TQM), crisis management, pharmacoeconomics, and antimicrobial stewardship programs.

Research Interest

Dr. Shouair’s research interests focus on clinical pharmacy, antimicrobial resistance, pharmacoeconomics, neonatology, and infectious diseases. She has led NICU-based studies on antibiotic protocols, contributing to improved neonatal care. Her work includes statistical studies on antimicrobial resistance in NICU departments, research on the effect of vitamin K supplementation in neonates receiving prolonged antibiotic therapy, and investigations into the role of anti-interleukin-6 in reducing COVID-19 mortality rates.

Her project on reducing Linezolid use was among the top 15 projects selected from 100 hospitals by the Egyptian Drug Authority.

Author Metrics

Dr. Shouair has authored and co-authored several research studies and clinical protocols, with her work focusing on antibiotic stewardship, NICU care, and COVID-19 treatment strategies. Her contributions in pharmacoeconomics and antimicrobial resistance have been recognized in hospital and governmental healthcare settings, making a significant impact on patient safety and cost-effective treatment strategies.

Conclusion

Dr. Amal Shouair is a highly suitable candidate for the Best Researcher Award in the field of Toxicology and Clinical Pharmacy. Her work in antimicrobial resistance, neonatology, and pharmacoeconomics has made a substantial impact on healthcare policies and hospital protocols. With additional focus on international collaborations and publications, she could further strengthen her standing as a global leader in clinical research.

Paula Abola| Toxicology | Best Researcher Award